Catalyst Pharmaceuticals Inc. (CPRX)

{tplLang.businessdescription | toLang tLang}

{ profileData.description }

{tplLang.ceo | toLang tLang}

{profileData.profile.details.ceo}

{tplLang.employees | toLang tLang}

{profileData.profile.details.employees | numeraljs '0,0'}

{tplLang.issuetype | toLang tLang}

{profileData.profile.details.issuetype | asIssueType}

{tplLang.sector | toLang tLang}

{profileData.profile.classification.sector}

{tplLang.industry | toLang tLang}

{profileData.profile.classification.industry}

{tplLang.toolname| toLang tLang}

There is no {tplLang.toolname| toLang tLang} currently available for {data.symbolstring}.

AbbVie Inc. (ABBV $226.08)
- $226.08 P/E (TTM): 109.43X Cap: $399.57B
- View ABBV Profile
- View Questions on ABBV
Eli Lilly and Company (LLY $1,010.31)
- $1,010.31 P/E (TTM): 49.63X Cap: $955.13B
- View LLY Profile
- View Questions on LLY
Cipher Pharmaceuticals Inc. (CPH $14.60)
- $14.60 P/E (TTM): 15.55X Cap: $370M
- View CPH Profile
- View Questions on CPH
- View Reports on CPH
Halozyme Therapeutics Inc. (HALO $63.33)
- $63.33 P/E (TTM): 14.41X Cap: $7.44B
- View HALO Profile
- View Questions on HALO
uniQure N.V. (QURE $21.33)
- $21.33 Cap: $1.65B
- View QURE Profile
- View Questions on QURE
Catalyst Pharmaceuticals Inc. (CPRX $23.53)
- $23.53 P/E (TTM): 13.42X Cap: $2.89B
- View CPRX Profile
- View Questions on CPRX

Q: Hi, could you suggest a couple each of your fav. small, mid and large cap biotech stocks and why you like them.

thanks, M

Read Answer Asked by Mark on October 08, 2025

Q: What's your opinion about these two stocks? Buy/Hold/Sell? Timeframe: 3-5 years. Risk tolerance: moderate.

Read Answer Asked by Paul on September 12, 2025

Q: Are there any news or downgrades for CPRX? It's down 3.5% on the up day. Do you still like/recommend this stock for healthcare holdings?

Read Answer Asked by Anit on August 26, 2025